Study of Antibiotic Spacer Design to Treat Infection After Hip Replacement (SPACERHIP)

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2014 by Rush University Medical Center
Sponsor:
Collaborators:
Thomas Jefferson University
Central DuPage Hospital
Information provided by (Responsible Party):
Peter N. Chalmers, MD, Rush University Medical Center
ClinicalTrials.gov Identifier:
NCT01373099
First received: June 6, 2011
Last updated: January 15, 2014
Last verified: January 2014
  Purpose

Infection remains one of the most difficult-to-treat complications of total hip arthroplasty. The gold standard treatment is two-stage removal of the prosthesis with later replacement of permanent implants.The first stage consists of removal of the infected arthroplasty components and the surrounding devitalized tissue, copious pulsed irrigation, and placement of a temporary antibiotic-impregnated cement spacer. This spacer is typically left in place six weeks, during which time the patient receives intravenous antibiotics. After the surgeon feels that the infection has been eradicated, or if a second debridement is required, a second operative procedure is performed. While the use of an antibiotic spacer is well accepted, whether the spacer should immobilize the hip (a so-called "static" spacer) or allow for range of motion (a so-called "articulating" spacer) is controversial. Proponents of static spacers argue that immobilization of the periarticular soft tissues aids in clearance of the infection and that these spacers are simpler to fashion intraoperatively. Proponents of articulating spacers argue that they improve hip function, prevent damage to the musculature surrounding the hip, allow easier reimplantation, improve hip function, and prevent dislocation following hip reimplantation. While good results have been described with both methods, comparative trials have been conflicting as to whether spacer design alters hip function, operative time, and dislocation rates. Equipoise exists within the literature, and no randomized clinical trial has been conducted to evaluate this issue.

The purpose of this study is to compare articulating and static antibiotic-impregnated spacers for the treatment of chronic periprosthetic infection complicating total hip arthroplasty through a prospective, randomized clinical trial. The goals of this trial are to determine the effect of spacer design upon eradication of infection, hip function, ease of reimplantation, and dislocation rates. The investigators hypothesize that articulating spacers will provide shorter operative times at replantation while improving hip function and hip dislocation rates following hip reimplantation.


Condition Intervention
Osteoarthritis
Hip Infection
Prosthetic Joint Infection
Complications; Arthroplasty, Infection or Inflammation
Complications; Arthroplasty
Procedure: Implantation of a static, non-articulating cement spacer.
Procedure: Implantation of an articulating spacer.

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Articulating Versus Static Antibiotic Loaded Spacers for the Treatment of Prosthetic Hip Infection

Resource links provided by NLM:


Further study details as provided by Rush University Medical Center:

Primary Outcome Measures:
  • Harris Hip Score [ Time Frame: outcome will be collected until 2 years post-operatively ] [ Designated as safety issue: No ]
    The Harris Hip score has been used extensively in the study of revision hip arthroplasty and has been found to be reliable and valid to determine hip arthroplasty outcomes.


Secondary Outcome Measures:
  • Operative time [ Time Frame: at the time of spacer revision, which would be up to a maximumup to 2 years after patient enrollment ] [ Designated as safety issue: No ]
  • Hip dislocation rates [ Time Frame: outcomes will be collected until 2 years post-operatively ] [ Designated as safety issue: No ]

Estimated Enrollment: 80
Study Start Date: August 2011
Estimated Study Completion Date: August 2018
Estimated Primary Completion Date: August 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Static Spacer
Patients in this group will be randomized to a static, nonarticulating, antibiotic-impregnated cement spacer.
Procedure: Implantation of a static, non-articulating cement spacer.
After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed using 3.0 g of Vancomycin and 1.0 g of Tobramycin for each 40 g packet of cement. Static spacers will be hand-made with a rod of antibiotic-impregnated cement and cement beads of sufficient quantity to fill the acetabulum.
Experimental: Articulating spacer
Patients in this group will be randomized to an articulating antibiotic-impregnated cement spacer.
Procedure: Implantation of an articulating spacer.
After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed using 3.0 g of Vancomycin and 1.0 g of Tobramycin for each 40 g packet of cement. Articulating spacers will be formed of antibiotic-impregnated cement using the Stage One system (Biomet, Warsaw, IN) sized to fit the endosteal and acetabular bone defect.

Detailed Description:

After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed using 3.0 g of Vancomycin and 1.0 g of Tobramycin for each 40 g packet of cement. Articulating spacers will be formed of antibiotic-impregnated cement using the Stage One system (Biomet, Warsaw, IN) sized to fit the endosteal and acetabular bone defect. Static spacers will be hand-made with a rod of antibiotic-impregnated cement and cement beads of sufficient quantity to fill the acetabulum.

Post-operatively, all patients will be made touch-down weight bearing protected with a walker or crutches. At the time of reimplantation, the joint will be aspirated and multiple cultures obtained along with intraoperative histopathological analysis to evaluate for persistent infection.

Data collected preoperatively will include age, gender, laterality, etiology of hip degeneration, comorbidities, Harris Hip score, infecting organisms and Paprosky femoral and acetabular bone loss classification. The Harris Hip score has been used extensively in the study of revision hip arthroplasty and has been found to be reliable and valid and will be determined preoperatively and at all follow-up visits.

Data collected at the time of implant removal and reimplantation will include operative time, blood loss, surgical approach, and need for an extended trochanteric osteotomy. Radiographs performed immediately following and just prior to reimplantation will be reviewed to determine if the spacer utilized has caused bone loss; bone loss to the cut bony surfaces will be confirmed intraoperatively. At each follow-up visits radiographic appearance, the Harris Hip Score, dislocation events, recurrence of infection, and the need for revision or reoperation of any kind on the hip will be determined.

All portions of this study will be part of conventional care except for randomization and collection of the Harris Hip Score. Which type of spacer is used currently depends upon the judgment of the attending surgeons and both are used routinely.

The primary outcome variable will be Harris Hip Score. A power analysis was conducted with the assistance of Dr. Mario Moric at Rush. Using the standard deviation of Harris Hip Scores from Hsieh and colleagues (2004) and Fehring and colleagues (1999), the largest previous studies reporting such data, Dr. Moric estimated 56 patients, 28 patients per group, would be needed to detect a clinically relevant difference of ten points. To account for attrition, our target total sample size will be 80 patients.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

1) Diagnosis of periprosthetic joint infection of a primary total hip arthroplasty with a planned two-stage exchange procedure.

Exclusion Criteria:

  1. Infection of a revision as opposed to a primary total hip arthroplasty
  2. Medically unfit for operative intervention
  3. Extensive bone loss preventing the use of an articulating spacer
  4. Soft-tissue defects that prevent the use of an articulating spacer
  5. Known allergy to polymethylmethacrylate, tobramycin or vancomycin.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01373099

Contacts
Contact: Peter N Chalmers, MD 3129425000 peter_chalmers@rush.edu
Contact: Craig Della Valle, MD 3129425000

Locations
United States, Illinois
Rush University Medical Center Recruiting
Chicago, Illinois, United States, 60612
Sponsors and Collaborators
Rush University Medical Center
Thomas Jefferson University
Central DuPage Hospital
Investigators
Principal Investigator: Craig Della Valle, MD Rush University Medical Center
Principal Investigator: Scott Sporer, MD Rush University Medical Center
Principal Investigator: Peter Chalmers, MD Rush University Medical Center
Principal Investigator: Javad Parvizi, MD Thomas Jefferson Hospital
Principal Investigator: Matt Austin, MD Thomas Jefferson Hospital
  More Information

Publications:

Responsible Party: Peter N. Chalmers, MD, Resident, Rush University Medical Center
ClinicalTrials.gov Identifier: NCT01373099     History of Changes
Other Study ID Numbers: SPACERHIP
Study First Received: June 6, 2011
Last Updated: January 15, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Rush University Medical Center:
arthroplasty
hip replacement
Osteoarthritis
knee Infection
Prosthetic Joint Infection
Complications; Arthroplasty, Infection or Inflammation
Complications; Arthroplasty

Additional relevant MeSH terms:
Arthritis, Infectious
Inflammation
Osteoarthritis
Pathologic Processes
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Infection
Anti-Bacterial Agents
Antibiotics, Antitubercular
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Antitubercular Agents

ClinicalTrials.gov processed this record on July 09, 2014